UBS analyst Jo Walton maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target of €110.00. The ...

Leerink Partners analyst David Risinger has maintained their bullish stance on SNYNF stock, giving a Buy rating yesterday. David Risinger has ...

Therefore, Sanofi's partnership with Sudair Pharma aims to address this gap and increase access to effective care for people ...

Despite its leadership in pharmaceutical products for diabetes, Sanofi is not a market leader in blood glucose meters and devices, with firms such as Abbott Diabetes Care and Bayer having a ...

Confounding data from a Pfizer clinical trial have rattled the field of gene therapy for Duchenne muscular dystrophy ...

Analysts at Zacks Research decreased their Q4 2025 earnings estimates for Sanofi in a research note issued on Tuesday, ...

Abbott's optimistic forecasts due to high sales of glucose monitors; legal issues with Moderna and GSK; J&J's talc case ...

Today, there’s an immunoscience renaissance happening, and Sanofi is pushing medical research in this field forward at a much ...

The insulin is facing supply shortages as diabetes patients increasingly turn to GLP-1 weight loss drugs such as Ozempic and ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2025, according to Statista. A large portion of that figure is from the oncology segment, which is expected ...

While these lucrative products cater to affluent markets, they leave a stark vacuum in access to essential diabetes management ... of Novo Nordisk’s retreat, Sanofi has announced ongoing ...